REGULATORY

MHLW Clarifies Position on Investigational Drug Info; No Generic Names Allowed on Companies’ Clinical Trial Websites

February 2, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pharmaceutical companies should not post the generic names or development codes of their investigational drugs on their clinical trial websites intended for the general public as it runs afoul of the Pharmaceuticals and Medical Devices (PMD) Law, a health ministry…

To read the full story

Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022

REGULATORY

Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…